Experts indicate monoclonal therapy of antibodies may prevent progression of COVID if timed right

New Delhi: Doctors from all around India agreed to show favourable results for monoclonal antibodies among high-risk patients by reducing illness severity and opportunities for admission. This test drug was implemented in the country at highest level when the second wave was reported every day with multiple COVID patients.

Trails of recovery have revealed that monoclonal antibody usage can be prolonged to 7-10 days. Experts also underlined that monoclonal antibodies used in advance in sero-negative autoimmune patients have helped to reduce the likelihood of severe disease and hospitalisation.

This was observed at the Emerging COVID-19 Treatment Therapies session organised by Integrated Health & Wellbeing (IHW) Council in association with Cipla. Some noted speakers and experts present at the event included Dr Randeep Guleria, Director, AIIMS, New Delhi, Dr Dhruva Chaudhary, Head, Department of Pulmonary and Critical care Medicine, PGIMS, Rohtak, and Dr Shashank Joshi, of Lilavati Hospital and Research Centre, Mumbai.

Speaking about Monoclonal antibodies as a treatment for COVID, Dr Joshi, said, “We can say monoclonal antibodies are a reasonable treatment based on the compelling data from elite trails for high-risk patients, even in people who have not developed any antibody. The first 48 to 72 hours of infection is the most opportune time for administering monoclonal antibodies, but most of the patients come after that. Now, we have data from recovery trials which show the use of monoclonal antibodies can be extended up to 7 to 10 days and in exceptional cases, can be used in hospitalised patients as well.”

Monoclonal antibodies are different from the commonly used steroids that are commonly used and perceived as the only drugs available for treatment, as was noted by Dr Chaudhary. The cost factor of using monoclonal antibodies however, is to be examined.

“Our treatment strategy has evolved and we are using both empirical and repurposed drugs. Monoclonal antibodies have been useful for patients with high risk of severe disease but more data is needed on its efficacy. Besides, the challenge is to ensure they are not used across the board. The bottom-line is when to give which drug and when not to use which drug. A lot of investment has been done in vaccine development but not in antivirals. We need to invest more in developing good antivirals that can be given easily to patients and useful in the long run,”Dr Guleria added.

Medically Speaking

Recent Posts

Harness the Power of Rice Water

Rice water, rich in inositol, antioxidants, vitamins, and minerals, protects hair from sunlight damage and…

2 hours ago

“8 Powerful Herbs and Supplements to Beat Bloating and Boost Your Gut Health Naturally”

Natural Remedies for Bloating: 8 Herbs and Supplements That Work Wonders for Your Gut Health…

2 hours ago

“Unlock the Power of Oil Pulling: Discover How This Simple Practice Improves Oral Health and Freshens Your Breath”

Benefits of Oil Pulling: Stops Bad Breath, Keeps Gums Healthy, But Can't Replace Brushing Oil…

2 hours ago

WHY DO YOU EXPERIENCE RUNNY NOSE AFTER EATING SPICY FOOD?

Spicy food – whether it’s a dash of chili in your curry, a spoonful of…

2 hours ago

“4 Simple Tests to Spot Adulterated Wheat Flour: Protect Your Health with These Easy Checks”

How To Identify Adulterated Wheat Flour? Try These 4 Easy Tests Wheat flour is a…

2 hours ago

“Unlock the Power of Jaggery: 10 Surprising Health Benefits of Eating It After Every Meal”

Reasons That Will Make You Eat Jaggery After Every Meal (Potential Health Benefits Inside) Jaggery,…

3 hours ago